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Objective
To develop contemporary and inclusive prostate cancer survivorship guidelines for the Australian setting.
Participants and Methods
A four-round iterative policy Delphi was used, with a 47-member expert panel that included leaders from key Australian
and New Zealand clinical and community groups and consumers from diverse backgrounds, including LGBTQIA people
and those from regional, rural and urban settings. The first three rounds were undertaken using an online survey (94–96%
response) followed by a fourth final face-to-face panel meeting. Descriptors for men’s current prostate cancer survivorship
experience were generated, along with survivorship elements that were assessed for importance and feasibility. From these,
survivorship domains were generated for consideration.
Results
Six key descriptors for men’s current prostate cancer survivorship experience that emerged were: dealing with side effects;
challenging; medically focused; uncoordinated; unmet needs; and anxious. In all, 26 survivorship elements were identified
within six domains: health promotion and advocacy; shared management; vigilance; personal agency; care coordination; and
evidence-based survivorship interventions. Consensus was high for all domains as being essential. All elements were rated
high on importance but consensus was mixed for feasibility. Seven priorities were derived for immediate action.
Conclusion
The policy Delphi allowed a uniquely inclusive expert clinical and community group to develop prostate cancer
survivorship domains that extend beyond traditional healthcare parameters. These domains provide guidance for
policymakers, clinicians, community and consumers on what is essential for step change in prostate cancer survivorship
outcomes.
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Introduction
In 2018 over 1.2 million men were diagnosed with prostate
cancer globally, with overall incidence expected to increase a
further 42% by 2030 [1]. As incidence rises, advances in
detection and treatment have led to improved survival rates
in many countries, with Australia reporting 90.6% 10-year
survival [2], the USA 98% [3], and the UK 84% [4]. Hence
the prevalence of prostate cancer continues to rise: in
Australia, more than 200 000 men are living with a previous
diagnosis [2,5]; 3 000 000 in the USA [6,7], and over 300 000
men in the UK [8]. Problematically, after diagnosis and
treatment many men (up to 40%) experience poorer quality
of life and satisfaction with life over the long term (10 years)
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[9] and, even with localized disease, one in five men will
experience persistent anxiety and depression 1 year after
treatment [10], with distress greater in men with advanced
disease [11]. Poorer long-term outcomes are associated with
androgen deprivation therapy, multiple comorbidities,
younger age at diagnosis, and socio-economic disadvantage
[9]. Survivorship care that seeks to enhance health and well-
being outcomes over both the short and longer term is
therefore crucial for this patient group.
Limitations of existing survivorship guidelines include an
over-reliance on expert opinion [12,13], invisibility of the
consumer voice [14,15], a lack of translation into policy and
practice [16], and, in the case of prostate cancer survivorship,
gaps in knowledge [17]. Perspectives about masculinity and
men’s health are notably absent [18]. Recent commentary
proposes that survivorship care for men with prostate cancer
needs to take into account unique disease-specific factors,
both clinical and biological, as well as the subjective patient
experience [12]. Given the increasing burden of prostate
cancer and the lack of clear progress in the development,
acceptance and delivery of quality prostate cancer
survivorship care, a different approach is needed that
connects current evidence, expert opinion and consumer
perspectives.
The Delphi technique is a widely used method that seeks to
forecast and elicit informed expert opinion and consensus in
a structured and iterative approach. In health, the Delphi
method has been used to develop the following: health system
performance, prescribing and disease indicators [19]; clinical
models of care [20,21]; patient outcome measure sets [22];
and cancer survivorship classifications [23]. The policy Delphi
[24] is appropriate for complex health policy issues and uses
panel participants with a range of potentially different
perspectives who are well informed and have a vested interest
in the issue at hand, and specifically considers feasibility as
well as importance [20,25]. This method is cost-effective as it
does not require multiple and ongoing committee meetings,
avoids constraining committee processes and, through expert
involvement, sets a platform for dissemination [26].
Accordingly, we undertook a policy Delphi to describe the
current state of prostate cancer survivorship in Australia and
New Zealand and identify survivorship domains and domain
elements for inclusion in care guidelines taking into account
evidence, importance, feasibility and consensus.
Participants and Methods
Participants
Using purposive sampling through consultation with leading
Australian (n = 46) and New Zealand (n = 1) clinical and
community groups we identified 47 potential panel members
who were leaders in the field with recognized authority in
prostate cancer and survivorship care or who were able to
represent the experiences of men with prostate cancer.
Australian participants spanned six jurisdictions (New South
Wales, n = 18; Queensland, n = 8; Victoria, n = 8; South
Australia, n = 7; Western Australia, n = 3; and the Australian
Capital Territory, n = 2). All of those invited agreed to
participate. The panel included 31 nationally leading clinical,
allied health, nursing and academic and community leaders
and 16 consumers who had experience in the provision of
support in the community (Table 1) from a range of
professional and academic organizations (Table 2).
Representatives from indigenous health, the LGBTIQ
community, rural and regional as well as urban consumers,
and partners of men with prostate cancer were included.
Health professional and academic leaders had between 15 and
40 years of experience with prostate cancer, and, for men,
their time since diagnosis ranged from 6 to 20 years
(Table 1). Sample sizes for policy Delphi range from 10 to 30,
with a maximum of 50 considered appropriate [25,26].
Procedure
A four-round policy Delphi was undertaken between 9
September 2019 and 20 February 2020, with ethical approval
from the University of Technology Sydney (Approval
#ETH19-3855). The first three rounds were administered
Table 1 Participant characteristics.
Demographic characteristics % (n)
Age
18–44 years 13 (6)
45–54 years 19 (9)
55–64 years 26 (12)
65–74 years 36 (17)
75–84 years 4 (2)
85+ years 2 (1)
Gender
Male 66 (31)
Female 34 (16)
Role*
Health professionals
Urologist 4 (2)
Medical oncologist 6 (3)
Radiation oncologist 4 (2)
General practitioner 4 (2)
Physiotherapist 2 (1)
Exercise physiologist 6 (3)
Registered nurse 9 (4)
Other (health professional) 19 (9)
Consumers
Patients 30 (15)
Partners 8 (4)
Family of survivors 4 (2)
Time since diagnosis for survivors, years Mean (range)
Patients 12 (6–20)
Partners 15 (9–23)
Health professional and academic leaders experience, years 16 (15–40)
*Some participants were health professionals who also have or had had prostate
cancer, therefore, numbers do not add up to 47.
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using the QualtricsXM survey platform, with the final round
conducted at a face-to-face meeting. Each survey was pilot-
tested in advance and revised as needed. Survey response
rates were 96% (n = 45) for the first survey round, 96%
(n = 45) for the second round and 94% (n = 44) for the third
round, and 28 panel members attended the face-to-face
meeting. In Round 1, 47 people replied but only 45 had
complete data. After Round 1, one of the expert panel
members withdrew from the project owing to a role change.
The purpose of Round 1 was generation of ideas and views
about prostate cancer survivorship. Open-ended questions
invited respondents to list three words describing the current
survivorship experience for men diagnosed with prostate
cancer and then to outline what domains they viewed as
essential for prostate cancer survivorship care. To stimulate
participant reflection, full-text article links to the ASCO
prostate cancer survivorship guidelines [13] and recently
proposed domains for a Cancer Survivorship Care Framework
[16] were provided.
In Round 2 a synthesized list of descriptors for the prostate
cancer survivorship experience generated in Round 1 were
provided for panel members to choose up to five words that
most closely represented men’s current experience. Next,
participants were asked to rate the survivorship care elements
synthesized from Round 1 for importance and feasibility (1 –
not important at all, to 7 – extremely important; 1 – not
feasible at all, to 7 – extremely feasible). Importance was
defined as the degree to which a survivorship element is of
significance or value to improving prostate cancer
survivorship care. Feasibility was the degree to which a
survivorship element can be achieved, performed or
implemented.
In Round 3 the survivorship elements from the previous
rounds were thematically analysed to derive survivorship
domains for the panel to consider the extent to which each
domain should be included in prostate cancer survivorship
guidelines (1 – not at all, to 7 – absolutely). For each domain,
an open-ended question invited further commentary and
suggestions for missing elements.
For Round 4, at a 1-day face-to-face meeting, participants
reviewed the evidence for intervention for each survivorship
domain through pre-reading and discussion of relevant
systematic literature reviews [17], consumer perspectives [14],
and a series of expert presentations. Participants were
assigned to groups for each of the survivorship domains, each
group was then asked to identify priority actions for change,
and to consider feasibility of change in their designated
domain to improve the survivorship experience in prostate
cancer. Each group reported back to the other expert panel
members on their identified priority actions. The expert panel
members and two clinician-researchers (A.K., M.F.) were then
given 10 votes each to vote on the top priority actions to
target for change to inform future implementation. The top
priorities for action were determined by the priority actions
that received over 50% of the combined votes.
Analysis
Data from each round were considered verbatim and then
underwent independent content and thematic analysis by three
authors (J.D., A.G., S.K.C.), followed by discussion and consensus
to provide synthesized data for the panel to consider in subsequent
rounds. There are no universally accepted rules for consensus in
the Delphi method. In the present study we determined the
direction of consensus on seven-point rating scales using score
categories of 6–7 as highly important/feasible/essential, 5 as
moderately important/feasible/essential, 4 as neutral; 3 as less
important/feasible/essential, and 1–2 as not important/feasible/
essential [27]. The direction of consensus was defined as the
proportion of agreement in either one agreement category (e.g.
‘highly important’), or across two contiguous categories according
to the consensus rule [27] (e.g. ‘highly important’ and ‘moderately
important’). The consensus rule was: high consensus – 70% in one
agreement category or 80% in two contiguous categories; moderate
consensus – 60% in one agreement category or 70% in two
contiguous categories; low consensus – 50% in one agreement
category or 60% in two contiguous categories; and no consensus –
less than 50% in one agreement category or less than 60% in two
contiguous categories [27,28].
Results
Experience of Prostate Cancer Survivorship
Round 1 elicited 135 words or phrases to describe the
prostate cancer survivorship experience from which 30
Table 2 Panel member organizational affiliations.
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Australia and New Zealand Urological Nurses Society
Australian Prostate Centre
Cancer Council Australia
Queensland Cancer Occupational Therapy Interest Group
Cancer Voices New South Wales
Centre for Research Excellence in Prostate Cancer Survivorship
Exercise and Sports Science Australia
Flinders Centre for Innovation in Cancer
Healthy Male
Macquarie Health
Medical Oncology Group of Australia
Peter MacCallum Cancer Centre
Primary Care Collaborative Cancer Clinical Trials Group
Prost! Exercise Group
Prostate Cancer Foundation of Australia
Prostate Cancer Foundation of New Zealand
Psychology Board of Australia
Royal Australian and New Zealand College of Radiologists
Urological Society of Australia and New Zealand
Regional and Major Urban Prostate Cancer Support Group Leadership
© 2020 The Authors
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unique words/phrases were identified. Of these, 18 were
negative, four neutral, and eight positive. In Round 2, the top
six words endorsed by at least 25% of the panel as best
describing men’s current prostate cancer survivorship
experience were: dealing with side effects; challenging;
medically focused; uncoordinated; unmet needs; and anxious
(Table 3).
Prostate Cancer Survivorship Care Elements and
Domains
In Round 1, participants described 310 elements of care that
were synthesized through content analysis to produce 26
unique prostate cancer survivorship elements. In Round 2,
most items were rated as very important with high consensus
(22 items) and the remaining four items were very important
to important with high consensus (Table 4). For feasibility,
six items were rated as very feasible to moderately feasible
with high consensus, three items as very feasible to
moderately feasible with moderate consensus and the
remaining 17 had either no [5] or low [12] consensus
(Table 5). Through thematic analysis [29] and data
consolidation [30] of these items, six domains of survivorship
care were elicited: health promotion and advocacy; shared
management; vigilance; personal agency; care coordination
and evidence-based survivorship interventions (see
Appendix 1 for domain definitions).
In Round 3, participants rated all six domains as very
important with high consensus (Table 6). In Round 4,
participants identified 31 priority actions for change across
the six domains of survivorship care (Table 7). Participants
then cast a total of 293 votes to identify the top priority
actions to target for change. Seven priorities for action
received over half of the combined votes (n = 163). These top
priority actions were: a patient communication kit for health
professionals; a ‘My Journey Kit’ from diagnosis for patients;
alternative delivery models to improve access; advocacy for
Medicare Benefit Schedule (Commonwealth) payments for
care programmes; exercise as an avenue for personal agency;
better use of technology; and innovative models for specialist
nurses (Table 8).
Discussion
Consistent with our previous research, this expert panel
described the current experience of prostate cancer survivorship
in Australia as medically focused, not well coordinated and
challenging, exacerbating the difficulty of treatment side effects
and leading to unmet needs and anxiety [14,21]. The burden of
prostate cancer in the individual has been well described, with
the chronic nature and prolonged natural history of this
disease, along with accumulated toxicities from existing and
emerging treatments, exacerbating the need for survivorship
guidelines [12]. Problematically, a survivorship response from a
policy, research and practice perspective has been slow to
emerge and where it does exist is fragmented [31]. The present
study applying the Delphi method as a policy practice planning
tool uniquely presents a collective high consensus statement
from the Australian and New Zealand clinical and consumer
community about the essential domains for prostate cancer
survivorship care. Six essential survivorship domains were
identified, each with important elements (Fig. 1), to guide
action not only in this context, but likely elsewhere. These
domains in practice will articulate closely with each other,
which we propose is a strength that mirrors the realities of life
as a cancer survivor where different domains of quality of life
intersect and influence long-term physical and mental well-
being and life satisfaction [9].
Health Promotion and Advocacy
Health promotion and advocacy is central to the early
detection of prostate cancer and survivorship care after
diagnosis and treatment by raising community awareness and
maintaining a public focus on men’s health. Key to this
domain is the provision of up-to-date information to increase
the Australian and New Zealand community’s knowledge of
men’s health and prostate cancer. Information should be
Table 3 Endorsement of prostate cancer survivorship descriptors.
Descriptors Endorsement % (n)
Dealing with side effects 78 (35)
Challenging 38 (17)
Medically focused 33 (15)
Uncoordinated 29 (13)
Unmet needs 29 (13)
Anxious 27 (12)
Emotional 24 (11)
Family relationships 22 (10)
Variable 20 (9)
Surveillance 18 (8)
Optimistic 18 (8)
Resilience 18 (8)
Mostly ok 18 (8)
Decision-making 16 (7)
Well-being 13 (6)
Confusing 13 (6)
Resigned 11 (5)
Distressing 11 (5)
Living 11 (5)
Relief 9 (4)
Learning 9 (4)
Positive 7 (3)
Transformative 7 (3)
Regret 7 (3)
Burdensome 4 (2)
Poor 2 (1)
Isolating 2 (1)
Helping 0 (1)
Diminished 0 (1)
Lifelong 0 (1)
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evidence-based, providing consistent messaging around
prostate cancer, and tailored to take into account health
literacy and preferences for different mediums [32,33].
Information should be targeted specifically to primary care
providers and community workers along with dedicated
training in men’s health promotion to work effectively with
men. Advocacy is required from the non-government sector
for the effective promotion of men’s health to government
and to health service providers and to engaging community
support. Advocacy is also required to bring attention to the
support needs of survivors and their families, including
advocating for programmes around peer support and self-
management. This involves facilitating public access to
information about prostate cancer, the provision of evidence-
based interventions and improving access to survivorship care
for all men and their families, including those living in rural
and remote areas, LGBTQIA people, indigenous people, and
people from culturally and linguistically diverse backgrounds
[34–36].
Shared Management
Shared management between patients and health
professionals is required to improve outcomes and ensure
quality survivorship care. Development of models which
facilitate informed decision-making around testing and
treatment and address physical and psychosocial effects,
comorbidities, advanced cancer symptoms, and palliative care
is a priority [37]. Clear explanation is required that palliative
care relates to the prevention and control of symptoms earlier
in the survivorship journey as well as to end-of-life issues.
Informed decision-making involves access to decision aids to
facilitate understanding of treatment options, side effects and
associated financial costs, as well as open communication and
delivery of consistent information. Shared management
extends to respecting a patient’s wishes to engage in decision-
making around care to the extent they prefer, involves
acknowledging and supporting the role family members and
carers play, and requires access to patient records. Once
shared and informed management decisions are made, these
decisions should be supported by effective care coordination,
with primary care providers and prostate cancer specialist
nurses playing a central role as navigators [21].
Vigilance
Vigilance in relation to the clinical surveillance of patients is
critical to prostate cancer survivorship. Vigilance from health
professionals across the survivorship continuum from diagnosis
to end-of-life care is necessary, with attentive surveillance of
physical and psychosocial effects, comorbidities, recurrence and
second cancers. This extends to monitoring psychosocial effects
Table 4 Frequency (%) of response regarding the degree to which each element of survivorship is important (Round 2; N = 45).
Consensus
(direction)
Very
important
(6–7)
n (%)
Moderately
important
(5)
n (%)
Neutral
(4)
N (%)
Less
important
(3)
n (%)
Not
important
(1–2)
n (%)
Management of advanced symptoms High (VI) 45 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Access to care High (VI) 45 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Palliative care High (VI) 44 (97.8) 1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0)
Multidisciplinary teams High (VI) 43 (95.6) 2 (4.4) 0 (0.0) 0 (0.0) 0 (0.0)
Managing physical effects High (VI) 43 (95.6) 1 (2.2) 1 (2.2) 0 (0.0) 0 (0.0)
Psychosocial care High (VI) 42 (93.3) 3 (6.7) 0 (0.0) 0 (0.0) 0 (0.0)
Up-to-date information High (VI) 42 (93.3) 3 (6.7) 0 (0.0) 0 (0.0) 0 (0.0)
Surveillance of recurrence and second cancers High (VI) 42 (93.3) 2 (4.4) 1 (2.2) 0 (0.0) 0 (0.0)
Care coordination High (VI) 42 (93.3) 3 (6.7) 0 (0.0) 0 (0.0) 0 (0.0)
Shared and informed decision High (VI) 41 (91.1) 3 (6.7) 1 (2.2) 0 (0.0) 0 (0.0)
Person-centred care High (VI) 41 (91.1) 3 (6.7) 1 (2.2) 0 (0.0) 0 (0.0)
Family support for the patient High (VI) 41 (91.1) 3 (6.7) 1 (2.2) 0 (0.0) 0 (0.0)
Prostate cancer specialist nurses High (VI) 40 (88.9) 5 (11.1) 0 (0.0) 0 (0.0) 0 (0.0)
Monitoring physical effects High (VI) 39 (86.7) 4 (8.9) 2 (4.4) 0 (0.0) 0 (0.0)
Exercise, physical activity and nutrition High (VI) 39 (86.7) 5 (11.1) 1 (2.2) 0 (0.0) 0 (0.0)
Health promotion High (VI) 39 (86.7) 3 (6.7) 1 (2.2) 1 (2.2) 1 (2.2)
Screening for psychosocial effects High (VI) 39 (86.7) 5 (11.1) 1 (2.2) 0 (0.0) 0 (0.0)
Self-management High (VI) 39 (86.7) 4 (8.9) 1 (2.2) 1 (2.2) 0 (0.0)
Management of comorbidities High (VI) 38 (84.4) 5 (11.1) 1 (2.2) 0 (0.0) 1 (2.2)
Maintaining intimate relationships High (VI) 38 (84.4) 7 (15.6) 0 (0.0) 0 (0.0) 0 (0.0)
Advocacy High (VI) 37 (82.2) 3 (6.7) 3 (6.7) 2 (4.4) 0 (0.0)
Surveillance of comorbidities High (VI) 37 (82.2) 7 (15.6) 0 (0.0) 1 (2.2) 0 (0.0)
Empowerment High (VI-MI) 35 (77.8) 8 (17.8) 1 (2.2) 1 (2.2) 0 (0.0)
Psychosocial care of family members High (VI-MI) 30 (66.7) 13 (28.9) 2 (4.4) 0 (0.0) 0 (0.0)
Financial assistance High (VI-MI) 28 (62.2) 9 (20.0) 6 (13.3) 2 (4.4) 0 (0.0)
Peer support High (VI-MI) 27 (60.0) 12 (26.7) 6 (13.3) 0 (0.0) 0 (0.0)
MI, moderately important; VI, very important.
© 2020 The Authors
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on partners and family members [38]. The level of vigilance
should be tailored to the changing needs of patients through
screening early on and then systematically over the
survivorship journey. Additional sources of information to
evaluate patients, including observations from partners and
other family members, are important to take into account.
Health professionals should take action on the outcomes of
clinical surveillance as required.
Personal Agency
Personal agency enables a patient’s ability to understand risk
factors and take steps to promote personal well-being;
therefore, a focus on personal agency and the ability of
individual patients to be self-aware in assessing their needs,
seek assistance when required, and manage their own health
is central to improving outcomes. By ’personal agency’ we
mean the capacity of an individual to initiate, execute and
manage their actions in response to the awareness and
ownership of health-related needs. Recognizing patients as
actors in building personal resilience, managing their own
health and with mastery in navigating the healthcare system
will lead to improved survivorship outcomes. Family
members and wider social support networks also play a key
role in supporting patients to achieve objectives. Patient
Table 5 Frequency (%) of response regarding the degree to which element of survivorship is feasible (Round 2; N = 45).
Consensus
(direction)
Very feasible
(6–7)
n (%)
Moderately
feasible (5)
n (%)
Neutral
(4)
n (%)
Less
feasible
(3)
n (%)
Not
feasible
(1–2)
n (%)
Surveillance of recurrence and second cancers High (VF-MF) 32 (71.1) 8 (17.8) 3 (6.7) 2 (4.4) 0 (0.0)
Up-to-date information High (VF-MF) 27 (60.0) 11 (24.4) 5 (11.1) 2 (4.4) 0 (0.0)
Monitoring physical effects High (VF-MF) 26 (57.8) 15 (33.3) 3 (6.7) 1 (2.2) 0 (0.0)
Management of advanced symptoms High (VF-MF) 25 (55.6) 15 (33.3) 3 (6.7) 1 (2.2) 1 (2.2)
Palliative care High (VF-MF) 22 (48.9) 15 (33.3) 6 (13.3) 2 (4.4) 0 (0.0)
Advocacy High (VF-MF) 20 (44.4) 16 (35.6) 4 (8.9) 4 (8.9) 1 (2.2)
Health promotion Moderate (VF-MF) 19 (42.2) 14 (31.1) 8 (17.8) 2 (4.4) 2 (4.4)
Exercise, physical activity and nutrition Low (VF-MF) 18 (40.0) 12 (26.7) 8 (17.8) 4 (8.9) 3 (6.7)
Family support for the patient Low (VF-MF) 18 (40.0) 13 (28.9) 9 (20.0) 2 (4.4) 3 (6.7)
Shared and informed decision Low (VF-MF) 17 (37.8) 12 (26.7) 11 (24.4) 5 (11.1) 0 (0.0)
Prostate cancer specialist nurses Low (VF-MF) 17 (37.8) 10 (22.2) 9 (20.0) 9 (20.0) 0 (0.0)
Screening for psychosocial effects Low (VF-MF) 17 (37.8) 10 (22.2) 12 (26.7) 4 (8.9) 2 (4.4)
Surveillance of comorbidities Moderate (VF-MF) 16 (35.6) 17 (37.8) 8 (17.8) 4 (8.9) 0 (0.0)
Peer support Low (MF-N) 15 (33.3) 10 (22.2) 16 (35.6) 3 (6.7) 1 (2.2)
Management of comorbidities Low (VF-MF) 15 (33.3) 13 (28.9) 10 (22.2) 4 (8.9) 3 (6.7)
Empowerment Low (VF-MF) 15 (33.3) 12 (26.7) 11 (24.4) 4 (8.9) 3 (6.7)
Person-centred care Low (VF-MF) 13 (28.9) 18 (40.0) 10 (22.2) 4 (8.9) 0 (0.0)
Managing physical effects Moderate (VF-MF) 13 (28.9) 22 (48.9) 7 (15.6) 2 (4.4) 1 (2.2)
Multidisciplinary teams Low (MF-N) 12 (26.7) 14 (31.1) 15 (33.3) 2 (4.4) 2 (4.4)
Psychosocial care Low (MF-N) 11 (24.4) 18 (40.0) 13 (28.9) 3 (6.7) 0 (0.0)
Self-management Low (VF-N) 10 (22.2) 18 (40.0) 10 (22.2) 6 (13.3) 1 (2.2)
Care coordination None (MF-N) 10 (22.2) 13 (28.9) 15 (33.3) 6 (13.3) 1 (2.2)
Maintaining intimate relationships None (MF-N) 9 (20.0) 12 (26.7) 12 (26.7) 7 (15.6) 5 (11.1)
Access to care None (MF-N) 8 (17.8) 17 (37.8) 14 (31.1) 5 (11.1) 1 (2.2)
Psychosocial care of family members None (N-LF) 5 (11.1) 8 (17.8) 17 (37.8) 12 (26.7) 3 (6.7)
Financial assistance None (N-LF) 1 (2.2) 8 (17.8) 15 (33.3) 14 (31.1) 7 (15.6)
LF, Less feasible; MF, moderately feasible; N, neutral; VF, very feasible.
Table 6 Frequency (%) of response regarding the degree to which each survival domain is essential (Round 3; N = 44).
Consensus
(Direction)
Very
essential
(6–7)
n (%)
Moderately
essential
(5)
n (%)
Neutral
(4)
n (%)
Less
essential
(3)
n (%)
Not
Essential
(1–2)
n (%)
Health promotion and advocacy High (VE) 39 (88.6) 1 (2.3) 3 (6.8) 0 (0.0) 1 (2.3)
Shared management High (VE) 41 (93.2) 0 (0.0) 3 (6.8) 0 (0.0) 0 (0.0)
Vigilance High (VE) 37 (84.1) 5 (11.4) 0 (0.0) 2 (4.5) 0 (0.0)
Personal agency High (VE) 41 (93.2) 3 (6.8) 0 (0.0) 0 (0.0) 0 (0.0)
Care coordination High (VE) 42 (95.5) 0 (0.0) 1 (2.3) 0 (0.0) 1 (2.3)
Evidence-based survivorship interventions High (VE) 43 (97.7) 0 (0.0) 1 (2.3) 0 (0.0) 0 (0.0)
VE, very essential.
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education and knowledge should be supported by the
provision of information across the spectrum of survivorship
care tailored to the health literacy levels of individual patients
[33]. A health professional workforce skilled in supporting
personal agency is required.
Care Coordination
Care coordination is required to get patients and families to
the right place at the right time for the right care once a
diagnosis has been made [39]. Care coordination in
consultation with patients and families is critical to
survivorship outcomes. Clinical teams, primary care
clinicians, nurses and allied health professionals, as well as
community-based health and welfare services, should all be
active participants. This requires systems to support the
sharing of relevant patient information between healthcare
teams, and referral to community-based peer support groups
where required. Underlying care coordination is the need for
healthcare teams to maintain a focus on delivering person-
centred care in developing plans to meet the needs of
individual patients. This includes approaching care in a men-
centred way, acknowledging that men-centred care is deeply
contextual and dynamic, but includes a consideration of how
healthcare services for men intersect with masculinity and
with men’s preferences for the design and delivery of prostate
cancer survivorship care [14,18]. Specific consideration of
access issues for indigenous men, those living in rural and
Table 8 Overall ranking of priority actions for change (Round 4).
Priority actions Votes
Patient communication kit for health professionals 32
‘My Journey Kit’ from diagnosis for patients 32
Alternative delivery models to improve access 22
Advocacy for MBS payment for care programmes 20
Exercise as an avenue for personal agency 20
Better use of technology 19
Innovative models for specialist nurses 18
Define care coordination 13
Use of community nurses/teams 13
Health professional education in health promotion 11
Australian online resources to connect people to local services 11
Define vigilance best practice for each patient group 9
Advocate for PBS support for surveillance tools 8
Health professional role 8
Peer support 7
Knowledge and information for patients, partners, family members and friends 7
Patient-centred 6
Empowering consumers to communicate 5
Engage partners, family members and friends to promote healthy choices 4
Improved communication 4
Improved health communication 4
Resources on side effects 4
High profile policy advocates 3
Communicating information about interventions 3
Continuous monitoring of consumer needs 2
Adaptability to changing circumstances 2
Information dissemination 2
Addressing personal attitudes through diverse avenues for support 2
Team-based care delivery 1
Vigilance pathways for health professionals 1
Health professional education on appropriate communication 0
MBS, the Medicare Benefits Schedule is a list of Medicare services subsidized by the
Australian Government; PBS, the Pharmaceutical Benefits Scheme provides medicines
to patients at a Government-subsidized price.
Health Promotion &
Advocacy Shared Management
Prostate Cancer Survivorship Essentials Framework
Vigilance
Personal Agency Care Coordination Evidence-based
Survivorship Interventions
Health promotion and advocacy is a central to the early
detection of prostrate cancer and survivorship care after
diagnosis and treeatment by raising community awareness
and maintaining a public focus on men’s health.
Shared management between patients and health
professionals is required. Facilitating informed decision making
around testing and tratment as well as addressing physical
and psychosocial effects, comorbidities, advanced cancer
symptoms, and palliative care is a priority.
Vigilance in relation to clinical surveillance of patients across
the survivorship continuum is necessary with attentive
surveillance of physical and psychosocial effects, comorbidities,
recurrence and second cancers.
Personal agency is important to a patient’s ability to understand
risk factors and take steps to promote personal well-being. By
‘personal agency’ we mean the capacity of an individual to
initiate, execute and manage their actions in response to the
awareness and ownership of health related needs.
Care coordination is required to get patients and families to the
right place at the right time for the right care once a diagnosis
has been made. Maintaining a focus on delivering persom-
centred care in developing plans to meet the needs of individual
patients is essential for health care teams.
Accessible evidence-based survivorship interventions are
essential in ensuring patients receive the best possible support
for their health and well-being.
Survivorship elements grouped under this domain:
Survivorship elements grouped under this domain: Survivorship elements grouped under this domain:
Survivorship elements grouped under this domain: Survivorship elements grouped under this domain:
Survivorship elements grouped under this domain:
Health promotion,
Up-to-date information,
Managing physical effects,
Management of comorbidities,
Management of advanced cancer symptoms,
Palliative care.
Shared and informed decision making, Monitoring physical effects,
Surveillance of comorbidities,
Surveillance of recurrence and second cancers.
Screening for psychosocial effects,Advocacy,
Access to care.
Family support for the patient.
Empowerment,
Self-management, Care coordination,
Psychosocial care,
Psychosocial care of family members,
Maintaining intimate relationship,
Exercise, physical activity & nutrition,
Peer support,
Financial assistance,
Prostate Cancer Specialist Nurses.
Multi-disciplinary teams,
Person-centred care.
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Fig. 1 Prostate cancer survivorship essentials framework.
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remote areas, and men from culturally and linguistically
diverse backgrounds is required.
Evidence-based Survivorship Interventions
Accessible evidence-based survivorship interventions ensure
patients receive the best possible support for their health and
well-being. Key evidence-based survivorship interventions
include psychosocial care, exercise and physical activity,
nutrition, peer support, financial assistance, and prostate
cancer specialist nurses. It is important that psychosocial care
interventions to maintain intimate relationships comprise
sexual health support tailored to individual men including
those in different age groups and from LGBTQIA
backgrounds.
Feasibility, Priorities and Limitations
It is not surprising that, while experts reached consensus
about the domains and elements of prostate cancer
survivorship and their importance, there was low consensus
around feasibility. The extent to which a survivorship
intervention element can be implemented will depend on the
healthcare, social and community systems in which each
individual man exists, as well as his own and his family’s
personal preferences. Healthcare inequities are widespread in
almost all societies globally, not only in Australia, and men’s
healthcare outcomes have specific challenges that are seldom
addressed in mainstream healthcare delivery [32]. In
response, our expert panel identified seven priority actions as
a practical platform for change. Action on each priority can
be expected to have an impact for men across the six
survivorship domains, and cumulatively could make a
measurable difference in the face of prostate cancer in this
country.
A limitation of this study is the Australian and New Zealand
setting, such that this framework may not generalize to
countries with markedly different cultural and health system
characteristics. However, we would argue that a workable
survivorship model requires this level of specificity and local
ownership and knowledge. Additionally, a number of the
participants in this Delphi study held leadership positions in
support groups in their community. Although these
participants had deep community understanding and
awareness of survivorship issues facing men with prostate
cancer, their views may not be representative of all men with
prostate cancer. Most importantly, the high participation and
response rates we report are evidence of rigour in our
approach and of the commitment of clinicians and
community to work together in novel ways to improve
outcomes for men with prostate cancer.
In conclusion, the policy Delphi provided a mechanism to
form a uniquely inclusive expert clinical and community
group from which a set of prostate cancer survivorship
domains were developed that extend beyond traditional
healthcare parameters. Guidance that spans personal agency,
health promotion and advocacy, shared management, care
coordination, evidence-based interventions, across to a shared
vigilance between the patient and the clinician, is a new way
of thinking about care. Each of these domains intersects or
articulates with each other and this mirrors both the patient
experience and how services operate at their best. New ways
of thinking will be needed as the healthcare burden of our
aging population grows, and as technological innovations in
personalized medicine emerge, with their attendant costs and
benefits [40–42]. New partnerships across disciplines that
include consumers are needed in order to respond to these
challenges, as well as to facilitate implementation [43]. This
study establishes these partnerships for prostate cancer
survivorship and provides a model for consideration in
cancer more broadly.
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Appendix 1
Prostate cancer survivorship essential domain names, elements and definitions
Domain name Domain elements Domain definition
Health promotion
and advocacy
1. Health promotion
2. Up-to-date information
3. Advocacy
4. Access to care
Health promotion and advocacy is central to the early detection of prostate cancer and survivorship care after
diagnosis and treatment by raising community awareness and maintaining a public focus on men’s health.
Key to this domain is the provision of up-to-date information to increase the Australian community’s
knowledge of men’s health and prostate cancer. It is important that up-to-date information is evidence-
based, provides consistent messaging around prostate cancer, and is tailored, taking into account varying
levels of health literacy and preferences for different mediums. Information should also be targeted
specifically to primary care providers and community workers along with dedicated training in men’s health
promotion to work effectively with men. Advocacy is required from the non-government sector for the
effective promotion of men’s health to government and to health service providers and to engaging
community support. Advocacy is also required to bring attention to the support needs of survivors and their
families, including advocating for programmes around peer support and self-management.
‘Making men’s health a priority’
This involves facilitating public access to up-to-date information, the provision of evidence-based interventions
and improving access to survivorship care for all men and their families. Including those living in rural and
remote areas, from LGBTQIA and culturally and linguistically diverse backgrounds
Shared
management
1. Shared and informed decision-
making
2. Management of comorbidities
3. Managing physical effects
4. Management of advanced
cancer symptoms
5. Palliative care
Once a diagnosis of prostate cancer has been made, shared management between patients and health
professionals is required to improve outcomes and ensure quality survivorship care. Developing models of
shared management to facilitate informed decision-making around testing and treatment, as well as
addressing physical and psychosocial effects, comorbidities, advanced cancer symptoms, and palliative care, is
a priority. Clear explanation that palliative care not only relates to end-of-life issues but also that the
prevention and control of symptoms earlier in the survivorship journey is required. Informed decision-
making that includes health professional and patient access to decision aids to facilitate understanding of
treatment options and side effects, associated financial costs, as well as open communication and delivery of
consistent information, is important. Shared management extends to respecting a patient’s wishes to engage
in decision-making around care to the extent they prefer. It is important for health professionals to
acknowledge the role family members and carers play in shared management for some patients and support
their involvement.
‘Fully informed decision-making’
Health professional access to patient records is important to informing shared management. Once shared and
informed management decisions are made by patients and health professionals, these decisions should be
supported by effective care coordination, with primary care providers and prostate cancer specialist nurses
playing a central role as navigators
Vigilance 1. Monitoring physical effects
2. Screening for psychosocial
effects
3. Surveillance of comorbidities
4. Surveillance of recurrence and
second cancers
Vigilance in relation to clinical surveillance of patients is critical to prostate cancer survivorship. Vigilance
from health professionals across the survivorship continuum from diagnosis to end-of-life care is necessary
with attentive surveillance of physical and psychosocial effects, comorbidities, recurrence and second cancers.
Health professionals’ vigilance is important in monitoring psychosocial effects on the partners and family
members of patients. The level of vigilance should be tailored to the changing needs of patients through
screening early on and then systematically over the survivorship journey. Additional sources of information
to evaluate patients, including observations from partners and other family members, are important to take
into account.
‘Surveillance of recurrence is very important and gives you hope as you survive your journey’
Vigilance includes health professionals taking action on the outcomes of clinical surveillance as required
Personal agency 1. Self-management
2. Empowerment
3. Family support for the patient
Personal agency is important to a patient’s ability to understand risk factors and take steps to promote
personal well-being. Therefore, a focus on personal agency and the ability of individual patients to be self-
aware in assessing their needs, seek assistance when required, and manage their own health is central to
improving outcomes. Family members and wider social support networks play a role in building personal
agency and supporting patients to achieve objectives
By ’personal agency’ we mean the capacity of an individual to initiate, execute and manage their actions in
response to the awareness and ownership of health-related needs. Recognizing ‘patients as actors’ in building
personal resilience, in managing their own health and with mastery in navigating the healthcare system will
lead to improved survivorship outcomes. Patient education and knowledge enables personal agency and
should be supported by the provision of information across the spectrum of survivorship care tailored to the
health literacy levels of individual patients. A health professional workforce skilled in supporting the personal
agency of patients is important
‘Survivors should be encouraged to assess their own needs, learn how and where to seek assistance. . .and what
questions they should be asking of health professionals’
© 2020 The Authors
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Table (continued)
Domain name Domain elements Domain definition
Care coordination 1. Care coordination
2. Multidisciplinary teams
3. Person-centred care
Care coordination is required to get patients and families to the right place at the right time for the right care
once a diagnosis has been made.
‘Guidance navigating the health system’
Care coordination in consultation with patients and families is critical to survivorship outcomes. Clinical teams,
primary care clinicians, nurses and allied health professionals as well as community-based health and welfare
services should all be active participants in Care coordination. This requires systems to support the sharing of
relevant patient information between healthcare teams, and referral to community-based peer support groups
where required.
‘A central healthcare professional connecting all the services, appointments and treatments’
Underlying care coordination is the need for healthcare teams to maintain a focus on delivering person-centred
care in developing plans to meet the needs of individual patients. This includes approaching care in a men-
centred way, acknowledging that men-centred care is deeply contextual and dynamic but includes a
consideration of how healthcare services for men intersect with masculinity and in the context of this study
with men’s preferences for the design and delivery of prostate cancer survivorship care. Specific consideration
of access issues to care coordination for men living in rural and remote areas and men from culturally and
linguistically diverse backgrounds is required.
‘Whole of person care. . .creation of personal packages’
Evidence-based
survivorship
interventions
1. Psychosocial care
2. Psychosocial care of family
members
3. Maintaining intimate
relationships
4. Exercise, physical activity and
nutrition
5. Peer support
6. Financial assistance
7. Prostate cancer specialist nurses
Accessible evidence-based survivorship interventions are essential in ensuring patients receive the best possible
support for their health and well-being. Key evidence-based survivorship interventions include psychosocial
care, exercise and physical activity, nutrition, peer support, financial assistance, and prostate cancer specialist
nurses.
‘Management of a well-planned exercise programme to meet your needs is a great help, and makes you feel
good about yourself’
Psychosocial care interventions to maintain intimate relationships that include sexual health support tailored to
individual men including those in different age groups and from LGBTQIA backgrounds are important
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